All relevant data are within the paper.

Introduction {#sec001}
============

Poliomyelitis is a highly contagious disease caused by a virus of the *Enterovirus* genus, belonging to the *Picornaviridae* family, known as *Poliovirus* and composed by a 7,500 nucleotides (+) single stranded RNA molecule \[[@pone.0169391.ref001],[@pone.0169391.ref002]\]. Three different serotypes of wild *Poliovirus* were identified and classified as type 1, type 2 and type 3 \[[@pone.0169391.ref003]\]. No specific therapy is available against the virus, but effective inactivated and attenuated vaccines are essential to prevent the disease. Since the development of the first vaccines by Salk in 1955 and Sabin in 1960 \[[@pone.0169391.ref004],[@pone.0169391.ref005]\], *Poliovirus* study greatly improved, taking advantage of cell cultures to isolate the virus from infected people \[[@pone.0169391.ref006],[@pone.0169391.ref007]\], microcarrier technology \[[@pone.0169391.ref008],[@pone.0169391.ref009]\] and simian cell lines for large-scale production of infected cells for vaccine manufacture \[[@pone.0169391.ref010]--[@pone.0169391.ref014]\].

Immortalization of animal and human cells, derived from primary cell cultures, is a phenomenon mainly due to genetic mutations or infections by oncogenic viruses, which can result in the appearance of transformed features and tumorigenic properties. Furthermore, cells can undergo several modifications during *in vitro* cultivation, resulting in the appearance of novel biochemical, biological and genetic characteristics that differ from primary or diploid cell ones. This represents an important issue in order to establish the biosafety of the cell lines used as substrates and to monitor the possible transmission of animal pathogens to human recipients \[[@pone.0169391.ref015]\].

Among continuous cell lines, the human HeLa cell line, naturally contaminated by human *Papillomavirus*, revolutionized the study of *Poliovirus* biology. On the other hand, Vero cells, widely used in *Poliovirus* vaccine manufacturing, became immortalized through a spontaneous, unknown process and they acquired tumorigenic properties with increasing *in vitro* passage levels \[[@pone.0169391.ref016]--[@pone.0169391.ref018]\]. Moreover, recent studies have demonstrated that the *in vitro* establishment of two African green monkey kidney derived cell lines, named BS-C-1 and CV-1, gave rise to transformed colonies and tumor formation in the rat model \[[@pone.0169391.ref018]--[@pone.0169391.ref020]\].

The aim of this research was to identify cell lines free of any transformation ability and tumorigenicity, suitable for *Poliovirus* vaccine production. In this respect, thirteen simian cell lines have been screened *in vitro* and *in vivo* for transformation and tumorigenicity features and their permissiveness to *Poliovirus* infection investigated, in comparison with other well-established substrates.

Materials and Methods {#sec002}
=====================

Cell lines {#sec003}
----------

All the investigated simian cell lines reported in [Table 1](#pone.0169391.t001){ref-type="table"} were stored at the Italian Biobank of Veterinary Resources of IZSLER, the OIE Collaborating Centre for Veterinary Biological Biobank (Brescia, Italy; [www.ibvr.org](http://www.ibvr.org)) and are available upon request. All these are continuous, spontaneously immortalized cell lines, exception made for CYNOM-K1, CV-1 (finite cell lines) and 4MBr-5 (EFG-dependent line). The investigations were performed at the passages indicated.

10.1371/journal.pone.0169391.t001

###### Cell lines used in the study.

![](pone.0169391.t001){#pone.0169391.t001g}

                                    Cell line                           Species and Tissue Origin                            Original source and catalogue number   IZSLER Biobank code   Passage
  --------------------------------- ----------------------------------- ---------------------------------------------------- -------------------------------------- --------------------- ---------
  Tested cell lines                 BGMK                                Buffalo Green Monkey Kidney                          Flow Laboratories                      BS CL 07              95
  BS-C-1                            African Green Monkey Kidney         ATCC[°](#t001fn001){ref-type="table-fn"} CCL-26      BS CL 09                               66                    
  CYNOM-K1                          Monkey Cynomolgus Skin              ECACC[ˆ](#t001fn002){ref-type="table-fn"} 90071809   BS CL 221                              25                    
  CV-1                              African Green Monkey Kidney         ATCC CCL-70                                          BS CL 23                               45                    
  FRhK-4                            Fetal RhesusMonkey Kidney           ATCC CRL-1688                                        BS CL 115                              78                    
  FrP3                              Fetal Rhesus Monkey Kidney          ISS[\*](#t001fn003){ref-type="table-fn"}             BS CL 169                              32                    
  LLC-MK2                           Rhesus MonkeyKidney                 ATCC CCL-7                                           BS CL 57                               37                    
  MA-104                            Fetal Monkey Kidney                 University of Perugia, Italy                         BS CL 61                               33                    
  MARC-145                          Fetal Monkey Kidney                 MARC[•](#t001fn004){ref-type="table-fn"}             BS CL 127                              25                    
  NCTC cl 3526                      Rhesus Monkey Kidney                ATCC CCL-7.2 \[derivative of LLC-MK2\]               BS CL 70                               283                   
  RC 37                             Monkey Kidney                       University of Parma                                  BS CL 189                              13                    
  4647                              Monkey Vervet Kidney                ECACC 90091902                                       BS CL 223                              11                    
  4MBr-5                            Macaca Mulatta Monkey Lung          ATCC CCL-208                                         BS CL 222                              31                    
  Control or substrate cell lines   HeLa                                Human cervix epitheloid carcinoma                    ATCC CCL-2                             BS CL 20              105
  HEp-2                             Human larinx epidermoid carcinoma   ATCC CCL-23                                          BS TCL 23                              363                   
  LCP                               Lamb Choroid Plexus                 Reparto substrati cellulari, IZSLER                  BS PRC 21                              \-                    
  MRC-5                             Embryonic human lung                ATCC CCL-171                                         BS CL 68                               20                    
  RK13.6                            Rabbit Kidney                       Labtek[˜](#t001fn005){ref-type="table-fn"}           BS CL 196                              76                    
  Vero                              African green monkey kidney         ATCC CCL-81                                          BS CL 86                               124                   
  3T3BALB/c                         Mouse fibroblast                    ATCC CCL-6587                                        BS CL 82                               116                   

°American Type Culture Collection, USA;

ˆEuropean Collection of Authenticated Cell Cultures, UK;

\*IstitutoSuperiore di Sanità, Italy;

^•^Meat Animal Research Center, USA;

˜Labtek, Corsico, Milano (I).

Moreover, seven cell lines used as controls or as substrates are reported in a separate section of [Table 1](#pone.0169391.t001){ref-type="table"}. MRC-5, LLC-MK2 and RK13.6 were used as substrates in adventitious agents investigation, while HEp2 and 3T3BALB/c as positive and negative controls in tumorigenicity assays. LCP were infected with Maedi-Visna virus (VIR RE RSCIC 312) and used as retrovirus positive sample.

Furthermore, MRC-5 and LLC-MK2 cell lines were selected to prepare "master" batches of three types of *Poliovirus* (see *Poliovirus* propagation section).

Cells were cryopreserved in vapor phase nitrogen until use. After thawing at 37°C, they were diluted in MEM culture medium (Sigma-Aldrich, Milan, Italy), free of antibiotics, supplemented with 4mM L-glutamine (Sigma-Aldrich) and centrifuged at 125 g for 5 minutes at 20°C, in order to remove the dimethyl sulfoxide cryoprotectant agent. Cells were stained with Trypan Blue (Sigma-Aldrich), counted and checked for viability by a Cellometer^®^ Automated Cell Counter (Nexcelom Bioscience, USA). Finally, 1x10^5^ viable cells of each cell line were seeded in a 75 cm^2^-flask and incubated at 37°C in 5% CO~2~ in the below reported culture media, enriched with 10% (v/v) of Fetal Bovine Serum (FBS; Euroclone, Milan, Italy).

BGMK, BS-C-1, CYNOM-K1, HeLa, HEp2, LCP, LLC-MK2, MA-104, MARC-145, RK13.6 and Vero cell lines were amplified in MEM, while FRhK-4, FrP3, RC 37 and 4647 cell lines in D-MEM (Sigma-Aldrich). NCTC cl 3526 cell line was maintained in NCTC 135 medium (Thermo Fisher Scientific) and CV-1 in Eagle's basal medium in Hanks' BSS with amino acids and vitamins (Sigma-Aldrich). 4MBr-5 were propagated in Ham's F K12 medium(Thermo Fisher Scientific) with 2 mM L-glutamine, adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 30 ng/ml epidermal growth factor, while 3T3BALB/c and MRC-5 cells were grown in MEM supplemented with 1 mM sodium pyruvate (Sigma-Aldrich).

Microbiological testing {#sec004}
-----------------------

All cell lines were tested for bacteria, fungi and yeast contamination. Each cell suspension was inoculated in Agar Sabouraud, Triptic Soy Agar and Brain Heart Infusion microbiological media (Sigma-Aldrich). The mixtures were incubated for 5 days at 30°C and for 3 days at 37°C, respectively, and observed daily in order to detect any contamination. *Mycoplasma* infection was evaluated using the commercial MycoSensor PCR Assay Kit (M-Medical S.r.l., Milan, Italy) according to the manufacturer\'s instructions.

Virology assays {#sec005}
---------------

Virus contamination of each cell line was investigated by Real-Time PCR assay. HCMV (*Human Cytomegalovirus*), HIV (*Human Immunodeficiency Virus*), HSV-1 (*Herpes Simplex Virus1*), HSV-2 (*Herpes Simplex Virus2*), EBV (*Epstein-Barr Virus*), HBV (*Hepatitis B Virus*) and HCV (*Hepatitis C Virus*) were examined by artus^®^ RG PCR Kit (Qiagen, Milan, Italy), according to the manufacturer's instructions. HHV-6 (*Human Herpesvirus 6*), HHV-7 (*Human Herpesvirus 7*), HHV-8 (*Human Herpesvirus 8*) and HPV (*Human Papilloma Virus*) were evaluated by a Real Quality PCR kit (AB AnaliticaSrl, Padova, Italy), following the manufacturer's instructions. Finally, *Influenza virus* type A was examined using the primers M-for (`5’-AGATGAGTCTTCTAACCGAGGTCG-3’`), M-rev (`5’-TGCAAAAACATCTTCAAGTCTCTG-3’`) proposed by van de Brand and colleagues \[[@pone.0169391.ref021]\], the probe INF-M (`5’-TET- TCAGGCCCCCTCAAAGCCGA-BHQ1-3’`, \[[@pone.0169391.ref022]\]) and the QuantiTect Virus kit (Qiagen), according to the manufacturer's instructions. Positive and negative controls, provided by the manufacturer, have been included in each session.

*In vitro* testing for adventitious agents was performed in compliance with the European *Pharmacopoeia* recommendations (Cell substrates for the production of vaccines for human use) \[[@pone.0169391.ref023]\]. Cell culture samples and cell cryolisates were investigated on MRC-5, RK13.6 and LCC-MK2 cells grown in 24-well plates for adventitious viruses with the ability to induce cytopathic effect (CPE) (co-culture and cryolisate method). Briefly, 0.1 ml of each sample was inoculated on cell monolayers and, following adsorption for 30 minutes, cells were fed with the specific growth medium containing 3% (v/v) of FBS and incubated at 37°C in 5% CO~2~. After 7 days of growth, medium was renewed, while monolayers were observed daily for CPE for 14 days. On day 14, treated LCC-MK2 cells were removed from the incubator and tested for haemadsorption of guinea pig and chicken erythrocytes. Briefly, cell monolayers were washed and duplicate wells were overlaid with 0.5 ml of 0.5% (v/v) of guinea pig and chicken erythrocytes and, after 30 minutes of incubation at room temperature, examined for adsorption. As positive control H/A/WSN/33 (VIR RE RSCIC 50) influenza virus was used.

Cell cultures were also examined for the presence of retroviruses, using the Reverse Transcriptase Assay, colorimetric kit (ROCHE, Basel, Switzerland) for the quantitative determination of the viral Reverse Transcriptase (RT) activity. According to manufacturer's instructions, a calibration curve was prepared from HIV-1 RT included in the kit. For the lysis of the retroviruses, 40 μl of supernatant were mixed with 40 μl of Lysis Buffer. After 30 minutes of incubation at room temperature, 20 μl of the reaction mixture were added to each reaction and HIV-1 RT standard tube. Finally, samples were incubated at 37°C for 15 h. Samples and HIV-1 RT dilutions were transferred into the wells of the MP modules and incubated for 1 h at 37°C. The solution was completely removed and the strip was rinsed 5 times with 250 μl of Washing Buffer per well for 30 s. 200 μl of anti-DIG-POD working solution were added and incubated for 1 h at 37°C. The solution was completely removed and the washing steps were repeated. Finally, 200 μl of ABTS Substrate Solution were added and the plate was incubated at room temperature for 30 minutes. The absorbance was measured at 405 nm by using a Gen5 microplate reader (Biotek, Milan, Italy) and the effective RT activity was extrapolated from the standard curve.

Species of origin {#sec006}
-----------------

Species of origin for the considered cell lines was evaluated by isoenzyme analysis, using the Authentikit System (Innovative Chemistry, Marshfield, USA), according to the manufacturers protocol. Briefly, cells were submitted to the extraction process by dilution of cell pellet in a specific buffer included in the kit. The enzyme activity was quantified by addition, after serial steps, of the Quench-A-Zyme Reagent by spectrophotometer (BioTek). The profiles of glucose-6-phosphatedehydrogenase, lactate dehydrogenase, nucleoside phosphorylase, malate dehydrogenase, mannose phosphate isomerase peptidase B, and aspartate aminotransferase isoenzymes were evaluated by electrophoresis. Species of origin was determined by comparing the migration distance of the analyzed isoenzyme systems with the reference distances provided by the kit \[[@pone.0169391.ref024]\].

*In vitro* transformation assay {#sec007}
-------------------------------

All the selected cell lines were tested for tumorigenicity according to the European *Pharmacopoeia* \[[@pone.0169391.ref023]\]. Soft agar colony assay was performed as previously described \[[@pone.0169391.ref025]\]. Briefly, 1% agar noble (Becton Dickinson, NJ, USA) was mixed with 50% of 2X MEM free of antibiotics, supplemented with 20% FBS and stratified into 6-well plates (3 ml/well). After solidification at room temperature for 1 h, this layer was overlaid with 0.8 ml of 1x10^5^cells/well suspension diluted in a mixture composed by 50% MEM supplemented by 20% FBS, and 50% of 0.6% agar noble. Plates were incubated at 20°C to allow solidification and then maintained at 37°C in 5% CO~2~ for 4 weeks and inspected daily by optical microscopy. Samples were considered negative if no cell growth was observed in soft agar, while the presence of one or more multicellular aggregates was accounted as transformation evidence. HEp2 and 3T3BALB/c cells were used, respectively, as positive and negative control.

Tumorigenic evaluation {#sec008}
----------------------

Potential tumorigenic evolution of the cell line that resulted to be negative in soft agar assays was evaluated by *in vivo* (Nu/Nu mice) assay, according to the European *Pharmacopoeia* \[[@pone.0169391.ref023]\]. The experiment was approved by the ethic committee of IZSLER and performed in compliance with ethical standards, according to the Directive 2010/63/EU on the protection of animals used for scientific purposes. Positive (HEp2 cells) and negative (3T3BALB/c) controls were included. All cell culture systems were tested at the same time and this approach allowed us to use only one positive and negative control, respectively. This strategy was applied in order to reduce the number of mice included in the *in vivo* assay, according to 3Rs principles. For the same reason, the *in vivo* test was not performed on BS-C-1and CV-1 cell lines because literature data has already reported their capacity to induce tumors in laboratory animals \[[@pone.0169391.ref018], [@pone.0169391.ref020]\]. Finally, no cell lines that induced transformed colonies in soft agar medium were included in the *in vivo* assay.

For the test, 70 athymic, 30-day-old male mice (Nu/Nu genotype), received from Harlan Laboratories, were used. They were subdivided in seven groups of 10 mice each. Five groups were inoculated with FRhK-4, MA-104, CYNOM-K1, 4647 and 4MBr-5 cell lines; one group was injected with the HEp2 cell line (positive control) and, finally, a further group was inoculated with the 3T3BALB/c cell line (negative control). All animal experiments were conducted at IZSLER, Brescia. The animals were housed on sterile bedding and with water and feed *ad libitum*. Each group was injected subcutaneously with 0.2 ml of 10^7^ cell suspension of each cell line. Five mice from each group were sacrificed 20 days after the injection, while the others were observed daily for 12 weeks. At the end of the observation period, the animals were humanely euthanized (CO~2~ inhalation). A necropsy was carried out on each mouse with the aim of detecting tumors at the injection site and in other organs (regional lymph nodes, lung, brain, spleen, kidney and liver). The local area of injection, together with the organs, were collected for histological examination and stained by haematoxylin-eosin, as described by Ferrari et al. \[[@pone.0169391.ref026]\]. In the event of tumor formation, animals were euthanized before the end of the observation period, in order to avoid any needless pain. The test was to be considered invalid if fewer than 9 of the 10 animals injected with the HEp2 cells, used as the positive control, did not show progressively growing tumors.

*Poliovirus* propagation {#sec009}
------------------------

The *Poliovirus* attenuated strains LsC 2ab Sabin type 1 (VIR RE RSCIC 48), P712 Ch 2ab Sabin type 2 (VIR RE RSCIC 182) and Leon 12alb Sabin type 3 (VIR RE RSCIC 183) were gently provided by Dr. Medici (University of Parma). LsC 2ab Sabin type 1 was cultivated in MRC-5 cells, while P712 Ch 2ab Sabin type 2 and Leon 12alb Sabin type 3 in LLC-MK2. The viruses were inoculated in the selected cell line seeded in a 75 cm^2^ flask at 1 MOI with 0.5 ml of culture medium. Infected cells were incubated at 37°C in 5% CO~2~ for 60 minutes and then added to 20 ml of culture medium supplemented by 3% (v/v) FBS; finally, samples were incubated at 37°C in 5% CO~2~ for five days. Cultures were observed daily in order to detect CPE and frozen at -80°C when CPE reached 80%. Subsequently they were thawed at room temperature, centrifuged at 1,000 g for 30 minutes at 4°C, distributed in aliquots, and stored at -80°C. The infectious titers were calculated by the Reed and Müench method \[[@pone.0169391.ref027]\]. The infectious titres of *Poliovirus* batches were the following: *Poliovirus* LsC 2ab Sabin type 1: 10^6.24^ TCID~50~/ml; *Poliovirus* P712 Ch 2ab Sabin type 2: 10^7.24^ TCID~50~/ml; *Poliovirus* Leon 12alb Sabin type 3: 10^7.74^ TCID~50~/ml.

Replication of *poliovirus* types {#sec010}
---------------------------------

FRhK-4, CYNOM-K1, 4MBr-5 and 4647 cell lines resulted to be devoid of transformation/tumorigenic evolution and were investigated for permissiveness to *Poliovirus*. To do this, 4x10^4^ viable cells/cm^2^ were seeded in 25 cm^2^ flasks, incubated in MEM added to 10% (v/v) of FBS at 37°C in 5% CO~2~. At 80% confluence, cells were infected at 0.1 MOI. At 80% CPE, flasks were frozen at -80°C, thawed, centrifuged at 1,540 g for 20 minutes at 4°C and supernatant was distributed into aliquots and used to evaluate the infectious titre, according to Reed and Müench formula \[[@pone.0169391.ref027]\].

For virus titration, each cell line was seeded in 96-well plastic plates and incubated at 37°C in 5% CO~2~ for 24 hours. The virus suspensions, collected from the different cell cultures, were diluted from 10^−1^ to 10^−8^ in culture medium and each dilution was inoculated into the corresponding cell line. Five wells were inoculated with each dilution at a volume of 100 μl/ well. Control cells were added with culture medium. The plates were incubated at 37°C, 5% CO~2~ for 60 minutes and then each plate was added to 100 μl/well of culture medium supplemented by 3% (v/v) FBS and incubated at 37°C, 5% CO~2~ for 7 days. Cell cultures were checked daily for CPE and the infectious titers were evaluated at the end of the observation period. In parallel sessions, *Poliovirus* infection has been performed on Vero and HeLa cells, as reference lines for the production of *Poliovirus*, and the obtained infectious titers were compared. These tests were performed in triplicate and the mean infectious titers were calculated.

Statistical analysis {#sec011}
--------------------

Differences between datasets of *Poliovirus* infectious titers were checked by one-way ANOVA, followed by a Dunn\'s post-hoc test for multiple comparisons. The significance threshold was set at P\<0.05 (Prism 5, GraphPad Software).

Results {#sec012}
=======

Microbiological testing and virology assays {#sec013}
-------------------------------------------

The cell lines tested proved to be free of microbial and mycoplasma contamination. No virus, including adventitious agents and retroviruses, has been detected in the selected cell lines. Results are reported in [Table 2](#pone.0169391.t002){ref-type="table"}.

10.1371/journal.pone.0169391.t002

###### Cell line quality and tumorigenicity parameters.

![](pone.0169391.t002){#pone.0169391.t002g}

  Cell line          Bacterial and mycoplasma contamination   Viral contamination   *In vitro* tranformation ability   *In vivo* tumorigenicity
  ------------------ ---------------------------------------- --------------------- ---------------------------------- ----------------------------------------
  **BGMK**           **-**                                    **-**                 \+                                 nd
  **BS-C-1**         **-**                                    **-**                 **-**                              \+[°](#t002fn002){ref-type="table-fn"}
  **CYNOM-K1**       **-**                                    **-**                 **-**                              **-**
  **CV-1**           **-**                                    **-**                 **-**                              \+[°](#t002fn002){ref-type="table-fn"}
  **FRhK-4**         **-**                                    **-**                 **-**                              **-**
  **FrP3**           **-**                                    **-**                 \+                                 nd
  **LLC-MK2**        **-**                                    **-**                 \+                                 nd
  **MA-104**         **-**                                    **-**                 dubious                            **-**
  **MARC-145**       **-**                                    **-**                 \+                                 nd
  **NCTC cl 3526**   **-**                                    **-**                 \+                                 nd
  **RC 37**          **-**                                    **-**                 \+                                 nd
  **4647**           **-**                                    **-**                 **-**                              **-**
  **4MBr-5**         **-**                                    **-**                 **-**                              **-**

nd: not done; + and - symbols indicate presence and absence of contaminating agents or transformation/tumorigenic ability;

° reported by Furesz et al. \[[@pone.0169391.ref018]\] and Johnson et al.\[[@pone.0169391.ref020]\]

Species of origin {#sec014}
-----------------

The isoenzyme test confirmed the monkey origin of all cell lines selected for the study, whereas the MRC-5 proved to be of human derivation as expected. No cross-contamination was detected.

*In vitro* transformation assay {#sec015}
-------------------------------

Cell lines reported in the higher section of [Table 1](#pone.0169391.t001){ref-type="table"} were investigated for their *in vitro* transformation ability. The results of the investigation showed that BGMK, FrP3, LLC-MK2, MARC-145, NCTC cl 3526 and RC 37cell lines induced transformed colonies in soft agar medium. These colonies began to appear at about 7 days after seeding ([Fig 1](#pone.0169391.g001){ref-type="fig"}) and then they increased gradually in number and size. This behavior was similar to that observed for the HEp2 cell line, used as positive control. In contrast, no transformed colonies were observed for the negative control 3T3BALB/c cell line, as well as BS-C-1, CYNOM-K1, CV-1, FRhK-4, 4647, and 4MBr-5 cell lines. All these samples remained negative until the end of the experiment (day 30). Results obtained from MA-104 cells were not clear, since cellular aggregates were detected, but their features were different from those observed in positive samples ([Fig 1](#pone.0169391.g001){ref-type="fig"}).

![Soft agar colony assay results.\
Representative captures of *in vitro* transformation assay results are reported for each investigated cell line.](pone.0169391.g001){#pone.0169391.g001}

Tumorigenic evaluation and histology {#sec016}
------------------------------------

Cell lines that did not display transformed colonies *in vitro* were applied for further investigations to test *in vivo* tumorigenic properties. The mice injected with CYNOM-K1, FRhK-4, 4647 and 4MBr-5 cell lines did not develop any tumor formation during the observation period. The same finding was observed for the mice inoculated with the 3T3BALB/c cell line (negative control; a representative capture is reported in [Fig 2A](#pone.0169391.g002){ref-type="fig"}). The group injected with the positive control (HEp2) developed a hyperplastic tumor at the inoculation area, as expected. In particular, nodules were already observed about 10 days after the injection and gradually increased in size ([Fig 2B](#pone.0169391.g002){ref-type="fig"}). They appeared smooth, uniform and globular (10 mm Ø); later they developed a multi-globular shape and increased in size (20 mm Ø). At necropsy, a tumour was detected only at the cell injection site of the skin; no other macroscopic alterations in the other organs and tissues were detected.

![Tumorigenic evaluation and histology.\
Representative captures of the absence (A) and presence (B) of a nodular lesion, localized at the site of injection of cells, in treated nude mice. In Panel C histological sections derived from cell-treated mice are reported.](pone.0169391.g002){#pone.0169391.g002}

At the two necropsy times (20 days and 12 weeks after the injection) no tumors were detected in skin of the *inoculum* area, lymph nodes, lungs, brain, spleen, kidneys and liver of the mice injected either with the selected cell lines under investigation or with the 3T3BALB/c cell line.

The histology carried out on tissue samples taken from mice injected with HEp2 cells showed the presence of polygonal cells in subcutaneous and dermal tissues; the nuclei of such cells were irregular in shape, with evident nucleoli (atypical mitosis); moreover, neoplastic cells were observed in the vessels. These alterations were restricted to the *inoculum* site. The tissues and organs of the animals injected with either CYNOM-K1, FRhK-4, 4MBr-5, 4647 cell lines, or those treated with the negative control 3T3BALB/c cells, did not show any inflammatory process ([Fig 2C](#pone.0169391.g002){ref-type="fig"}). In fact the injected cells were completely re-absorbed within a few days (in mean seven days).

Concerning MA-104 cells, the presence of a foreign body granuloma was detected at the injection *inoculum* site (data not shown). The results of the *in vitro* and *in vivo* tests are summarized in [Table 2](#pone.0169391.t002){ref-type="table"}.

Replication of *poliovirus* types {#sec017}
---------------------------------

All *Poliovirus* types replicated in all the investigated cell lines, as well as in Vero and HeLa cells, tested simultaneously as reference substrates for *Poliovirus* propagation and vaccine manufacturing. The infectious titers obtained in different assayed cells relative to attenuated Sabin strains type 1, 2 and 3, are reported in [Fig 3](#pone.0169391.g003){ref-type="fig"} in Panel A, B and C, respectively. TCDI~50~/ml data are reported as log10 mean ± standard error of the mean and analysed as indicated in material and methods section. Concerning LsC 2ab Sabin type 1 and P712 Ch 2ab Sabin type 2, TCID~50~/ml infectious titers ranged between 10^7.24^ and 10^8.16^, while Leon 12alb Sabin type 3 between 10^3.83^ and 10^8.50^. They replicated into cells without showing any dissimilarity between the different substrates, exception made for the observed tendency of all investigated cell lines in being more permissive to *Poliovirus* Leon 12alb Sabin type 3 propagation than HeLa and Vero. In particular, FRhK-4 cells showed to be significantly more sensitive to Leon 12alb Sabin type 3, compared with the simian reference cell line Vero (TCID~50~/ml mean: 10^8.50^ versus 10^3.83^).

![Susceptibility of cell lines to *Poliovirus*.\
Attenuated *Poliovirus* Sabin LsC 2ab Sabin type 1 (Panel A), P712 Ch 2ab Sabin type 2 (B) and Leon 12alb Sabin type 3 (C) infectious titers obtained on the indicated cell lines. Data are reported as TCID~50~/ml log~10~ mean ± standard error of the mean. Asterisk indicates a P value \< 0.05 significance between the two data sets marked by the line.](pone.0169391.g003){#pone.0169391.g003}

Discussion {#sec018}
==========

Cell cultures are widely used as substrates for the production of many biotechnological and biological products for human use, such as viral vaccines. Since the use of biological material may lead to potential contamination with known and unknown extraneous agents, cell substrates must be properly tested in order to avoid adverse features in patients. In this respect, the guidelines provided by the International Regulatory Agencies (European Medicines Agency, European *Pharmacopeia*, U.S. Food and drug Administration, World Health Organisation) \[[@pone.0169391.ref023], [@pone.0169391.ref028]--[@pone.0169391.ref030]\] require cell line free of any adventitious agents, eubacteria and cross-contaminants. In particular, continuous cell lines may represent a risk for the recipients of the biologicals, since they may vehicle oncogenic and viral components derived from the immortalization event (serial subcultivation of a primary cell culture of a human or animal tumor, transformation by oncogenic viruses, *in vitro* spontaneous transformation). For these reasons, cell cultivation history has to be clearly reported and transformation and tumorigenicity properties properly evaluated. Currently, the use of several tumorigenic cell lines is accepted for the manufacturing of viral vaccines, upon risk-benefit evaluation. For example, Vero cells are still used in *Poliovirus* vaccine production, although recent data showed growing evidence of tumorigenicity acquisition during serial subcultivation \[[@pone.0169391.ref016]--[@pone.0169391.ref018]\].

The aim of this study was to characterize different simian cell lines and assess their suitability for large-scale production. In particular, different aspects were investigated: microbiological evaluation, species of origin, potential *in vitro* and *in vivo* tumorigenic evaluation and *Poliovirus* amplification.

Microbiological results demonstrated the absence of viral and mycoplasma contamination and the isoenzyme test confirmed the monkey origin for all the analyzed cell lines.

The most crucial point regarding *in vitro* and *in vivo* tumorigenic evaluation permitted to express some interesting considerations.

Among the thrirteen cell lines investigated, only six (BS-C-1, CV-1, FRhK-4, CYNOM-K1, 4647, 4MBr-5) did not induce *in vitro* transformed colonies. Inconclusive findings were found for MA-104 cell line, since its soft-agar colonies appeared to be morphologically different from those observed in positive control.

Since the *in vitro* transformation results do not completely overlap with *in vivo* tumorigenicity ones, these cell lines were also injected into athymic mice, resulting free of any tumorigenic characteristics. In particular, CYNOM-K1, FRhK-4, 4MBr-5, 4647 cell lines did not show any evidence of macroscopic pathological tumors; necropsy was performed in order to collect sample for histological analysis. The obtained outcomes demonstrated the absence of pathological lesions either of neoplastic or inflammatory origin for all the selected cell lines.

BS-C-1 and CV-1 cell line were not assayed because already published data reported their tumorigenic features \[[@pone.0169391.ref018]--[@pone.0169391.ref020]\]. Among the five tested cell lines, results of the *in vivo* tumorigenicity test confirmed the data obtained from the transformation assay performed through the *in vitro* test and they both indicate no transformation features. The lack of previous studies reporting *in vivo* investigation of the tested lines allows no comparison of the results.

FRhK-4, CYNOM-K1, 4647, 4MBr-5 cell lines allowed the growth of the three viral types of attenuated Sabin *Poliovirus* as well as Vero and HeLa cells, with even superior performance in the case of Leon 12alb Sabin type 3. Since they resulted not transformed, devoid of tumorigenicity and characterized by a good replication capacity, these cells may represent alternative substrates for *Poliovirus* production to primary cell cultures from monkey kidneys, or other potentially tumorigenic cell lines, as Vero \[[@pone.0169391.ref031]\]. However, the continuous growth of FRhK-4 and 4647 cells, compared to the finite CYNOM-K1 cell line and the EGF-dependent 4MBr-5 \[[@pone.0169391.ref032], [@pone.0169391.ref033]\], make these cell lines more indicated for a large-scale production. Finally, another practical parameter to take in consideration is the *in vitro* growth of these cell lines. It was noticed a different trend in the doubling time of each biological substrate. As described in literature \[[@pone.0169391.ref034]\], Vero cells grow in 24--48 hours until a 70%-80% of confluence that represents a correct percentage for viral amplification use. During the present study, FRhK-4 and 4647 cells, as above mentioned, demonstrated a doubling time similar to Vero cells (48 hours) in comparison to CYNOM-K1 and 4MBr-5, that reach 70%-80% of confluence after 72 or more hours of incubation.

These results outlined the importance of a deep and constant monitoring of biological substrates, in order to highlight all potential risks related to the uncontrolled serial amplification. Cell batches for biological manufacturing should be maintained at established *in vitro* passages and properly tested according to the good laboratory practice and international guidelines.
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